Flu Vaccination Prevents Thousands of Hospitalizations Among Seniors in France
Flu vaccination prevented an average of 9,073 hospitalizations per year among people over 65 in France over the last three winters, the national public health agency Santé publique France reported on Thursday, November 19.
The finding comes as this winter’s campaign, opened on October 13, has already reached more than 7.5 million people, according to figures franceinfo obtained.
The study, covered by franceinfo and France Inter, covers the 2023-2024, 2024-2025 and 2025-2026 seasons. It lands at a delicate moment: last winter’s epidemic killed 12,000 people, the agency reminded, and fewer than one in two at-risk French residents gets the shot each year.
“It’s rare to be able to talk about hospitalizations we manage to avoid with an extremely simple prevention tool, one of the simplest in the world,” said Étienne Pot, director general of Santé publique France, in an interview with France Inter, according to franceinfo. “One injection, and you avoid a hospitalization,” he repeated.
- Flu vaccination has kept an average of 9,073 patients over 65 out of French hospitals each year since the winter of 2023-2024, per Santé publique France.
- Influenza still sends 44,000 people over 65 to hospital annually, mostly those over 75, and caused 12,000 deaths last season.
- Vaccine effectiveness averages 41% across 18 measured winters — about 50% when the vaccine matches circulating strains, 36% when the virus has drifted.
44,000 hospitalizations, mostly over 75
The agency’s burden estimate is stark. Influenza is responsible for 44,000 hospitalizations per year among people over 65, and the study indicates the toll concentrates overwhelmingly among the oldest — those over 75. The three seasons analyzed span a period in which France recorded, by the agency’s count, 12,000 flu deaths in the most recent epidemic alone.

Those figures explain why the avoided-hospitalization number carries such weight in the agency’s communication. Prevention of severe disease, rather than prevention of infection itself, is where the vaccine’s value shows most clearly in the data.
What the effectiveness numbers actually show
Santé publique France puts seasonal vaccine effectiveness at 40% to 60% against symptomatic flu. The vaccine is not an absolute shield, the agency cautioned, but it limits the most severe forms — and it remains, in the health authorities’ assessment, the most effective way to protect the most fragile.
A separate analysis adds historical texture to that range. Drawing on 18 winters of measurements, it found effectiveness reaches 50% when the vaccine matches the circulating viruses but drops to 36% in winters when the virus has changed, averaging 41% overall. The two weakest winters in that series — 10% in 2004-2005 and 19% in 2014-2015 — were dominated by the H3N2 virus, though the analysis did not compare virus types directly, according to JeChange.
| Measure | Figure | Source |
|---|---|---|
| Hospitalizations avoided per year, over-65s (avg. since 2023-2024) | 9,073 | Santé publique France |
| Flu hospitalizations per year, over-65s | 44,000 | Santé publique France |
| Flu deaths last epidemic | 12,000 | Santé publique France |
| Effectiveness, matched winters (7 of 18) | 50.4% avg. | Study analysis |
| Effectiveness, drifted-virus winters (11 of 18) | 36.2% avg. | Study analysis |
| Effectiveness, all 18 winters | 41% avg. | Study analysis |
The mechanics behind the variation are well understood. The vaccine is manufactured months before winter, built on the strains authorities judge most likely to circulate. When the virus that eventually spreads drifts away from those strains — a mismatch researchers documented in 11 of the 18 winters studied — protection falls.
The authors of that analysis remained cautious: winters also differ in population immunity and prior vaccinations, so the link with vaccine-virus mismatch is an association, and their model places likely effectiveness for an incoming winter between 16% and 59%.
A coverage gap the numbers expose
Even reduced effectiveness prevents severe disease, and even drifted-virus winters still avoided, on average, 36% of grippes menant à une consultation, according to the analysis. The groups with the most to gain — people 65 and older, pregnant women, and those with chronic illnesses — are precisely the ones in whom flu most often turns complicated.
Yet coverage lags. On average, fewer than one in two at-risk people in France is vaccinated each year. Last season, 57% of seniors got the shot. This season, more than 7.5 million people in France have been vaccinated since the campaign opened on October 13, franceinfo reported — a very slight increase on the same point last year.
The vaccine is offered free of charge to people 65 and over, which removes cost as a barrier for the group that accounts for most severe cases.
Where the campaign goes from here
The agency’s message is deliberately plain, and the arithmetic behind it holds across both data sets: at 41% average effectiveness, vaccination is far from perfect, yet it has still kept 9,073 seniors a year out of hospitals that would otherwise have absorbed them during winter surges.
The study has now fixed in the record the figures that Santé publique France recalls: the flu epidemic caused 12,000 deaths last year and is responsible for 44,000 hospitalizations per year among people over 65, essentially among those over 75.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.